Buscar
Ascentage Pharma Group International
AAPGAñadir a la lista de seguimiento
17.425USD
-0.750-4.16%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.61BCap. mercado
--P/E TTM
Más Datos de Ascentage Pharma Group International Compañía
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Información de Ascentage Pharma Group International
Símbolo de cotizaciónAAPG
Nombre de la empresaAscentage Pharma Group International
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoYang (Dajun)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección68 Xinqing Road, Suzhou Industrial Park
CiudadSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Teléfono
Sitio Webhttps://www.ascentage.cn/
Símbolo de cotizaciónAAPG
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoYang (Dajun)
Ejecutivos de Ascentage Pharma Group International
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ascentage Pharma Group International?
Los cinco principales accionistas de Ascentage Pharma Group International son: Dr. Dajun Yang, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Ascentage Pharma Group International (AAPG)?
A fecha de 2026Q1, 25 instituciones poseen acciones de Ascentage Pharma Group International, con un valor de mercado combinado de aproximadamente 65.84K, lo que representa el 0.07% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -220958.00.